On the evening of the 28th, Kexing Biopharmaceuticals (688136.SH) announced that it has received notice of the approval of its introduced product - albumin-bound paclitaxel (Apexelsin) for injection by EUROPESE COMMISSIE for listing.
Albumin-bound paclitaxel has clinical advantages over ordinary paclitaxel injection and paclitaxel liposome, improving safety and patient compliance, with high clinical recognition. It has irreplaceable clinical value in the field of tumor treatment and is a mainstream first-line treatment recommended by the European Society for Medical Oncology (ESMO) guidelines for metastatic pancreatic cancer and non-small cell lung cancer, and a second-line treatment for breast cancer. Breast cancer is one of the most common cancer types in the European Union and breast cancer drugs have a large market space.
In recent years, China Meheco Group has gradually started to go global in the pharmaceutical industry. However, Kexing Biopharmaceuticals had already taken its core products abroad more than 20 years ago, and in recent years has introduced more than ten Chinese high-quality drugs to emerging markets to improve local patients' access to pharmaceuticals.
The approval of albumin-bound paclitaxel in the European Union is beneficial to enhance the company's competitiveness in the international pharmaceutical market, and also means that Kexing Biopharmaceuticals' commercialization process is expanding to the European market in addition to focusing on emerging markets. The European Union market is an important milestone in the company's overseas commercialization strategy. The registration work in many countries and regions outside the European Union is also rapidly advancing. With the successful listing of this product in the European Union in the future, Kexing Biopharmaceuticals will further expand the global sales of its products and serve more medical professionals and patients.